Recommendations for the Use of Clinical Data in Premarket No

This guidance provides information for situations when clinical data may be necessary to demonstrate substantial equivalence in a 510(k) submission.

Related Keywords

, Drug Administration , Guidance Issuing Office , Radiological Health , Submit Comments , Biologics Evaluation , Evaluating Substantial Equivalence , Premarket Notifications ,